查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1947443

真實世界證據（RWE）解決方案市場：依組件（資料集、服務）、應用（藥物研發、市場准入、上市後監測）、最終用戶（製藥和生物技術公司、支付方、醫療服務提供者）和地區劃分 - 全球預測（～2036年）

Real-World Evidence (RWE) Solutions Market by Component (Datasets, Services), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 263 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

全球真實世界證據解決方案市場預計在預測期（2026-2036年）內將以 12.2%的年複合成長率成長，從2026年的39億美元成長到2036年的約 89億美元。

本報告對全球五大主要地區的真實世界證據解決方案市場進行了詳細分析，重點關注當前市場趨勢、市場規模、近期發展以及至2036年的預測。基於廣泛的二級和一級研究以及對市場現狀的詳細分析，本報告對關鍵產業驅動因素、限制因素、機會和挑戰的影響進行了分析。

推動真實世界證據解決方案市場成長的關鍵因素包括慢性病發病率上升、對個人化醫療的日益重視、全球向價值醫療模式的轉變，以及藥物研發和商業化過程中對真實世界證據的日益廣泛應用。此外，醫療系統的快速數位化、人工智慧和機器學習等先進技術的整合、監管機構對真實世界證據在決策中的認可，以及證據生成日益複雜化，預計都將為真實世界證據解決方案市場的企業創造巨大的成長機會。

主要市場趨勢

人工智慧在進階分析中的應用：影響真實世界證據解決方案市場的關鍵趨勢之一是將人工智慧（AI）和機器學習深度整合到分析平台中。人工智慧演算法可以處理大量、複雜的資料集，識別模式，預測結果，並產生僅靠人工分析無法實現的假設。自然語言處理技術能夠分析非結構化的臨床記錄，而機器學習演算法可以從龐大的電子健康記錄（EHR）資料庫中識別臨床試驗患者，並建立疾病進展的預測模型。這一趨勢正推動市場從描述性分析轉向預測性和規範性分析，從真實世界資料中釋放新的價值。

日益關注端到端真實世界證據（RWE）服務和策略合作夥伴關係：另一個關鍵趨勢是對涵蓋整個證據產生生命週期（從研究設計和資料收集到分析和報告）的全面、端到端 RWE 服務的需求不斷成長。生命科學公司越來越傾向於尋求能夠提供全面解決方案而非零散的、基於專案的服務的策略合作夥伴。這推動了行業整合，大型資料分析公司收購專業的RWE 公司並建立整合能力。端到端服務提供者提供整合平台和深厚的治療領域專業知識，使客戶能夠將 RWE 生成融入其核心運營，從早期研發到商業化和上市後活動。

監管機構的認可和新興指南：包括 FDA 和 EMA 在內的監管機構已製定明確的路徑和指南，將 RWE 納入其決策流程，這大幅促進了對 RWE 解決方案的信任和投資。監管政策的明朗化加速整個產業的採用，並為證據的生成和利用創造新的機會。

市場區隔

依組成部分

依組成部分劃分，預計到2026年，資料集部分將佔據整個真實世界證據解決方案市場的最大佔有率。這一主導地位主要歸功於高品質、經過整理的資料的重要性，而這正是任何真實世界證據研究的基礎。資料集部分包含多種資料來源，包括電子病歷（EMR）、電子健康記錄（EHR）、理賠資料、病患登記資料和多源資料集。這些資料集的價值在於其規模、縱向特性以及能夠分析患者隨時間推移的就醫歷程。能夠有效連接和整合不同資料集以建立全面患者檔案的資料提供者在市場中具有優勢。來自不同醫療機構的真實世界資料日益豐富，以及對資料品質和標準化的日益重視，推動對精選資料集的持續需求。

然而，預計在預測期內，諮詢和分析領域的年複合成長率將最高。隨著真實世界資料的數量和複雜性持續呈指數級成長，對專業知識和先進分析工具的需求也變得越來越重要，這些工具能夠幫助企業從中獲得有意義的洞見。該領域涵蓋研究設計、生物統計學、流行病學和衛生經濟學的服務，以及利用人工智慧（AI）和機器學習的先進分析平台。對方法有效、符合規範且能夠產生可靠、可操作洞見的真實世界證據（RWE）研究的需求，推動諮詢和分析服務的成長。各組織越來越意識到，僅僅擁有資料是不夠的；需要專家指導才能將原始資料轉化為策略性商業智慧。

依應用領域劃分

依應用領域劃分，預計到2026年，市場准入和償付/覆蓋決策領域將佔據整個真實世界證據解決方案市場的最大佔有率。該領域的領先地位反映了在當今成本受限的醫療保健環境下，向支付方證明產品價值的重要性。支付方越來越需要強而有力的證據來支持新產品的真實世界價值，然後再做出有利的償付決定。真實世界證據（RWE）用於建立經濟模型、進行比較療效研究，並證明產品對患者預後和醫療資源利用的影響。這些證據對於製造商進行價格談判、獲得藥品目錄收錄以及實現市場准入目標非常重要。

藥物研發和審批是另一個關鍵應用領域，預計在預測期內將快速成長。真實世界證據正被策略性地用於最佳化臨床試驗設計、加速患者招募，並在某些情況下作為臨床試驗的外部或合成對照組，尤其是在罕見疾病和腫瘤領域。包括FDA和EMA在內的監管機構正日益接受真實世界證據（RWE）用於標籤擴展和新產品審批，這是該領域成長的關鍵驅動因素。上市後監測正成為一個新的應用領域，製造商日益利用RWE在產品上市後監測產品的安全性、有效性和真實世界表現。

依最終使用者劃分

依最終用戶劃分，預計到2026年，製藥、生技和醫療器材產業將佔據最大的市場佔有率。這些機構是RWE解決方案的主要用戶，並在產品生命週期的各個階段（從早期開發到商業化和上市後活動）都加以利用。支付者和醫療服務提供者是一個重要且快速成長的最終用戶群體，他們越來越依賴RWE來最佳化醫療覆蓋決策、臨床方案和醫療服務策略。在這些不同的終端使用者類別中，RWE（真實世界證據）融入醫療保健決策流程推動市場持續擴張。

區域分析

對該產業的詳細區域分析提供了對五大主要區域（北美、歐洲、亞太、拉丁美洲以及中東和非洲）及其主要國家的深入定性和定量見解。北美將繼續保持領先地位，在2026年佔據全球真實世界證據解決方案市場最大的市場佔有率。這一優勢主要歸功於其高度發達的醫療保健基礎設施、數位健康技術的廣泛應用以及FDA制定的清晰的RWE監管框架。北美擁有許多世界領先的RWE公司和龐大的製藥產業，而製藥業正是這些解決方案的主要消費者。此外，北美擁有先進的支付方環境，強調實證決策。對健康資訊科技和巨量資料分析的大量投資進一步鞏固了該地區的領先地位。

歐洲擁有全球第二大真實世界證據解決方案市場，這主要得益於各國政府對健康資料研究的大力支持，以及諸如歐洲健康資料空間（EHDS）等目的是促進跨境安全存取健康資料的舉措。儘管資料環境分散和嚴格的GDPR 法規帶來了挑戰，但循證醫學倡議和監管協調為市場的持續成長提供了支撐。德國、法國和英國等國家在真實世界證據的採納和實施方面處於領先地位。

預計亞太地區將在預測期內實現最快成長。這一加速成長的驅動因素包括醫療保健支出不斷增加、中國和印度等國家醫療保健系統的快速數位化以及對生物醫學研發的日益重視。隨著當地監管機構在運用真實世界證據方面日益成熟，以及跨國製藥公司在該地區擴大業務，對綜合性真實世界證據解決方案的需求預計將顯著成長。拉丁美洲以及中東和非洲地區由於醫療保健投資的成長和實證醫學實踐的日益普及，也呈現出新興機會。

目錄

第1章 引言

第2章 研究方法

第3章 執行摘要

  • 依組件劃分的市場分析
  • 依應用劃分的市場分析
  • 依最終用戶劃分的市場分析
  • 依地區劃分的市場分析
  • 競爭分析

第4章 市場洞察

  • 市場驅動因素
    • 日益關注個人化醫療與價值醫療
    • 藥物研發成本上升與延誤
    • 監管機構對真實世界證據（RWE）的接受度不斷提高
  • 市場限制因素
    • 資料隱私與安全關注點
    • 缺乏標準化的研究方法
  • 市場機會
    • 新興經濟體
    • 日益關注端到端真實世界資料（RWE）服務
  • 市場挑戰
    • 資料品質與完整性問題
  • 市場趨勢
    • 人工智慧的整合
    • 藥物研發和商業化中 RWE 的應用日益廣泛
  • 波特五力分析

第5章 全球真實世界證據解決方案市場（依組件劃分）

  • 資料集
    • 分散式資料集
      • 電子病歷（EMR）、電子健康記錄（EHR）和臨床資料
      • 計費和計費資料
      • 藥局資料
      • 產品與疾病登記資料
      • 基因組資料
      • 其他分散式資料集
    • 整合資料集
  • 諮詢與分析

第6章 全球真實世界證據解決方案市場（依應用領域劃分）

  • 市場准入與償付/承保決策
  • 藥物研發與核准
    • 腫瘤學
    • 神經病學
    • 免疫學
    • 心血管疾病
    • 其他治療領域
  • 上市後監測
  • 醫療器材研發與審批
  • 其他應用

第7章 全球真實世界證據解決方案市場（依最終用戶劃分）

  • 製藥公司、生技公司及醫療器材製造商
  • 醫療支付方
  • 醫療服務提供方
  • 其他最終用戶

第8章 真實世界證據解決方案市場：依地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 亞太其他地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭格局

  • 關鍵成長策略
  • 競爭概覽
  • 主要公司市場佔有率/排名

第10章 公司簡介

  • IQVIA Holdings Inc.
  • Icon plc
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Oracle Corporation
  • Elevance Health, Inc.
  • Clinigen Group Plc
  • Cognizant Technology Solutions Corporation
  • Revvity, Inc.
  • SAS Institute Inc.
  • Parexel International Corporation
  • Healthverity, Inc.

第11章 附錄

簡介目錄
Product Code: MRHC - 104253

According to the research report titled, 'Real-World Evidence (RWE) Solutions Market by Component (Datasets, Services), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036,' the global real-world evidence solutions market is expected to reach approximately USD 8.9 billion by 2036 from USD 3.9 billion in 2026, at a CAGR of 12.2% during the forecast period (2026-2036).

The report provides an in-depth analysis of the global real-world evidence solutions market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the real-world evidence solutions market include the rising incidence of chronic diseases, increasing focus on personalized healthcare, a global shift toward value-based care, and the growing adoption of RWE in drug development and commercialization. Additionally, the rapid digitalization of healthcare systems, integration of advanced technologies like artificial intelligence and machine learning, regulatory acceptance of RWE for decision-making, and the rising complexity of evidence generation are expected to create significant growth opportunities for players operating in the real-world evidence solutions market.

Key Market Trends

Integration of Artificial Intelligence for Advanced Analytics: A key trend shaping the RWE solutions market is the deep integration of artificial intelligence and machine learning into analytics platforms. AI algorithms can process massive, complex datasets to identify patterns, predict outcomes, and generate hypotheses that would be impossible for human analysis alone. Natural language processing enables analysis of unstructured clinical notes, while machine learning algorithms identify eligible patients for trials from large EHR databases and create predictive models for disease progression. This trend is transitioning the market from descriptive analytics toward predictive and prescriptive analytics, unlocking new levels of value from real-world data.

Rising Focus on End-to-End RWE Services and Strategic Partnerships: Another major trend is the growing demand for comprehensive end-to-end RWE services spanning the entire evidence generation lifecycle, from study design and data sourcing through analysis and reporting. Life sciences companies are increasingly seeking strategic partners who can provide holistic solutions rather than fragmented, project-based services. This has led to consolidation activity, with larger data and analytics players acquiring specialized RWE firms to build integrated capabilities. End-to-end providers offer integrated platforms and deep therapeutic area expertise, enabling clients to embed RWE generation into core operations from early research and development through commercialization and post-market activities.

Regulatory Acceptance and Guidance Development: Regulatory bodies including the FDA and EMA have established clear pathways and guidance for incorporating RWE into decision-making processes, significantly boosting confidence and investment in RWE solutions. This regulatory clarity is accelerating adoption across the industry and creating new opportunities for evidence generation and utilization.

Market Segmentation

Based on Component

By component, the Datasets segment is expected to account for the largest share of the overall real-world evidence solutions market in 2026. This dominance is primarily attributed to the fundamental importance of high-quality, curated data as the raw material for any RWE study. The datasets segment comprises diverse data sources including electronic medical records (EMR), electronic health records (EHR), claims data, patient registries, and integrated datasets that combine multiple sources. The value of these datasets lies in their scale, longitudinal nature, and ability to enable analysis of patient journeys over extended periods. Data providers who can successfully link and integrate disparate datasets to create comprehensive patient profiles command premium positioning in the market. The increasing availability of real-world data from diverse healthcare settings and the growing emphasis on data quality and standardization are driving sustained demand for curated datasets.

However, the Consulting & Analytics segment is expected to grow at the fastest CAGR during the forecast period. As the volume and complexity of real-world data continue to expand exponentially, the demand for specialized expertise and advanced analytical tools to derive meaningful insights becomes increasingly critical. This segment encompasses services for study design, biostatistics, epidemiology, health economics, and access to advanced analytics platforms powered by artificial intelligence and machine learning. The requirement for methodologically sound, regulatory-grade RWE studies that generate credible, actionable insights is driving accelerated growth in consulting and analytics services. Organizations are increasingly recognizing that data alone is insufficient; they require expert guidance to transform raw data into strategic business intelligence.

Based on Application

By application, the Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the overall real-world evidence solutions market in 2026. This segment's dominance reflects the critical importance of demonstrating product value to healthcare payers in today's cost-constrained healthcare environment. Payers are increasingly demanding robust evidence of a new product's real-world value before granting favorable reimbursement decisions. RWE is utilized to develop economic models, conduct comparative effectiveness research, and demonstrate how products impact patient outcomes and healthcare resource utilization. This evidence is essential for manufacturers to negotiate pricing, secure formulary placement, and achieve market access objectives.

The Drug Development & Approvals segment represents another major application area and is expected to grow at a rapid pace during the forecast period. Real-world evidence is being strategically leveraged to optimize clinical trial design, accelerate patient recruitment, and in certain cases, serve as external or synthetic control arms for clinical trials, particularly in rare diseases and oncology. The regulatory acceptance of RWE for label expansions and even initial product approvals by agencies including the FDA and EMA represents a major catalyst driving growth in this segment. Post-Market Surveillance represents an emerging application area as manufacturers increasingly utilize RWE to monitor product safety, effectiveness, and real-world performance following market launch.

Based on End User

By end user, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the market in 2026. These organizations are major consumers of RWE solutions, utilizing them throughout the product lifecycle from early development through commercialization and post-market activities. Payers and Healthcare Providers represent significant and growing end-user segments as they increasingly rely on RWE to optimize coverage decisions, clinical protocols, and care delivery strategies. The integration of RWE into healthcare decision-making processes across these diverse end-user categories is driving sustained market expansion.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global real-world evidence solutions market with the largest market share. This dominance is primarily attributed to the presence of a well-developed healthcare infrastructure, high adoption of digital health technologies, and a clear regulatory framework for RWE established by the FDA. North America is home to many of the world's leading RWE companies, a large pharmaceutical industry that represents a major consumer of these solutions, and a sophisticated payer landscape that heavily relies on evidence-based decision-making. The significant investment in healthcare information technology and big data analytics further solidifies the region's leading position.

Europe represents the second-largest market for real-world evidence solutions, driven by strong government support for health data research and initiatives like the European Health Data Space (EHDS), which aims to facilitate secure, cross-border access to health data. While navigating the fragmented data landscape and strict GDPR regulations presents challenges, the commitment to evidence-based healthcare and regulatory harmonization supports sustained market growth. Countries including Germany, France, and the United Kingdom are at the forefront of RWE adoption and implementation.

Asia-Pacific is projected to be the fastest-growing region during the forecast period. This accelerated growth is fueled by rising healthcare expenditure, rapid digitalization of healthcare systems in countries including China and India, and a growing focus on biomedical research and development. As local regulatory bodies become more sophisticated in their utilization of RWE, and as multinational pharmaceutical companies expand their operations across the region, the demand for comprehensive RWE solutions is expected to accelerate significantly. Latin America and the Middle East & Africa represent emerging market opportunities with growing healthcare investments and increasing adoption of evidence-based healthcare practices.

Key Players

The key players operating in the global real-world evidence solutions market are IQVIA Holdings Inc., Icon plc, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Oracle Corporation, Elevance Health, Inc., Clinigen Group Plc, Cognizant Technology Solutions Corporation, Revvity, Inc., SAS Institute Inc., Parexel International Corporation, and Healthverity, Inc., among others. These companies compete based on the breadth and quality of their data assets, the sophistication of their analytical platforms, their therapeutic area expertise, and their ability to provide strategic, end-to-end solutions that meet the evolving needs of the life sciences industry and healthcare payers. Market consolidation has characterized the industry, with larger players acquiring specialized RWE firms to build comprehensive capabilities and expand geographic presence.

Key Questions Answered in the Report-

  • What is the current revenue generated by the real-world evidence solutions market globally?
  • At what rate is the global real-world evidence solutions market demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global real-world evidence solutions market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of component, application, and end user are expected to create major traction for the service providers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global real-world evidence solutions market?
  • Who are the major players in the global real-world evidence solutions market? What are their specific service offerings in this market?
  • What are the recent strategic developments in the global real-world evidence solutions market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Real-World Evidence Solutions Market Assessment -- by Component

  • Datasets
  • Services (Consulting & Analytics)

Real-World Evidence Solutions Market Assessment -- by Application

  • Drug Development & Approvals
  • Market Access & Reimbursement/Coverage Decisions
  • Post-Market Surveillance

Real-World Evidence Solutions Market Assessment -- by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Payers
  • Healthcare Providers

Real-World Evidence Solutions Market Assessment -- by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
    • 2.3.2. Bottom-Up Approach
    • 2.3.3. Top-Down Approach
    • 2.3.4. Growth Forecast
  • 2.4. Assumptions for the Study

3. Executive Summary

  • 3.1. Overview
  • 3.2. Market Analysis, by Component
  • 3.3. Market Analysis, by Application
  • 3.4. Market Analysis, by End User
  • 3.5. Market Analysis, by Geography
  • 3.6. Competitive Analysis

4. Market Insights

  • 4.1. Introduction
  • 4.2. Global Real-World Evidence Solutions Market: Impact Analysis of Market Drivers (2026-2036)
    • 4.2.1. Increasing Focus on Personalized Healthcare and Value-Based Care
    • 4.2.2. Rising Drug Development Costs and Delays
    • 4.2.3. Growing Regulatory Acceptance of RWE
  • 4.3. Global Real-World Evidence Solutions Market: Impact Analysis of Market Restraints (2026-2036)
    • 4.3.1. Data Privacy and Security Concerns
    • 4.3.2. Lack of Standardized Methodologies
  • 4.4. Global Real-World Evidence Solutions Market: Impact Analysis of Market Opportunities (2026-2036)
    • 4.4.1. Emerging Economies
    • 4.4.2. Rising Focus on End-to-End RWE Services
  • 4.5. Global Real-World Evidence Solutions Market: Impact Analysis of Market Challenges (2026-2036)
    • 4.5.1. Data Quality and Completeness Issues
  • 4.6. Global Real-World Evidence Solutions Market: Impact Analysis of Market Trends (2026-2036)
    • 4.6.1. Integration of Artificial Intelligence
    • 4.6.2. Growing Adoption of RWE in Drug Development and Commercialization
  • 4.7. Porter's Five Forces Analysis
    • 4.7.1. Threat of New Entrants
    • 4.7.2. Bargaining Power of Suppliers
    • 4.7.3. Bargaining Power of Buyers
    • 4.7.4. Threat of Substitute Products
    • 4.7.5. Competitive Rivalry

5. Global Real-World Evidence Solutions Market, by Component

  • 5.1. Introduction
  • 5.2. Datasets
    • 5.2.1. Disparate Datasets
      • 5.2.1.1. EMR/EHR/Clinical Data
      • 5.2.1.2. Claims & Billing Data
      • 5.2.1.3. Pharmacy Data
      • 5.2.1.4. Product/Disease Registries Data
      • 5.2.1.5. Genomics Data
      • 5.2.1.6. Other Disparate Datasets
    • 5.2.2. Integrated Datasets
  • 5.3. Consulting & Analytics

6. Global Real-World Evidence Solutions Market, by Application

  • 6.1. Introduction
  • 6.2. Market Access & Reimbursement/Coverage Decisions
  • 6.3. Drug Development & Approvals
    • 6.3.1. Oncology
    • 6.3.2. Neurology
    • 6.3.3. Immunology
    • 6.3.4. Cardiovascular Diseases
    • 6.3.5. Other Therapeutic Areas
  • 6.4. Post-market Surveillance
  • 6.5. Medical Device Development & Approvals
  • 6.6. Other Applications

7. Global Real-World Evidence Solutions Market, by End User

  • 7.1. Introduction
  • 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-World Evidence Solutions Market, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. U.K.
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Rest of Asia-Pacific
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Dashboard
  • 9.4. Market Share/Ranking by Key Players

10. Company Profiles

  • 10.1. IQVIA Holdings Inc.
  • 10.2. Icon plc
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Oracle Corporation
  • 10.6. Elevance Health, Inc.
  • 10.7. Clinigen Group Plc
  • 10.8. Cognizant Technology Solutions Corporation
  • 10.9. Revvity, Inc.
  • 10.10. SAS Institute Inc.
  • 10.11. Parexel International Corporation
  • 10.12. Healthverity, Inc.

11. Appendix

  • 11.1. Questionnaire
  • 11.2. Available Customization